Journal Article

Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma

Clinical Lymphoma, Myeloma and Leukemia (2019) 19(10) e559-e563
DOI: 10.1016/j.clml.2019.06.008
16Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.
Get full text

Author supplied keywords

Cite

CITATION STYLE

APA

Damlaj, M., Alzayed, M., Alahmari, B., Alhejazi, A., Alaskar, A., & Alzahrani, M. (2019). Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 19(10), e559–e563. https://doi.org/10.1016/j.clml.2019.06.008

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free